{"raw_text": "Cannabis hopes for drug firm\n \n A prescription cannabis drug made by UK biotech firm GW Pharmaceuticals is set to be approved in Canada.\n \n The drug is used to treat the central nervous system and alleviate the symptoms of multiple sclerosis (MS). A few weeks ago, shares in GW Pharma lost a third of their value after UK regulators said they wanted more evidence about the drug's benefits. But now Canadian authorities have said the Sativex drug will be considered for approval.\n \n Approximately 50,000 people in Canada have been diagnosed with MS and 85,000 people are suffering from the condition in the UK. Many patients already smoke cannabis to relieve their symptoms.\n \n Now, GW Pharma's Sativex mouth spray could be legally available to MS sufferers in Canada within the next few months. This will be the first time a cannabis-based drug has been approved anywhere in the world, representing a landmark for GW Pharma and for patients with MS. Final approval in Canada should now be little more than a formality, analysts said, and the company expects full approval for Sativex early in 2005. \"We are delighted to receive this qualifying notice from Health Canada and look forward to receiving regulatory approval for Sativex in Canada in the early part of 2005,\" said GW Pharma executive chairman Dr Geoffrey Guy.\n \n The UK government granted GW Pharma a licence to grow the cannabis plant for medical research purposes. Satifex consists of a cannabis extract containing tetrahydrocannabinol and cannabidiol, a cocktail that has also proved effective in treating patients with arthritis. Thousands of plants are grown at a secret location somewhere in the English countryside. Despite hopes of regulatory approval last year, a series of delays has put back Sativex's launch in the UK. The latest news sent shares in GW Pharma up 8.5p, or 8.1%, to 113.5p.\n", "llama3.2:1b": "Cannabis hopes for drug firm GW Pharmaceuticals is set to be approved in Canada through a prescription cannabis drug called Sativex. \n\nSativex is used to treat the central nervous system and alleviate symptoms of multiple sclerosis (MS). It has already been approved in the UK and 85,000 people are suffering from MS in the country.\n\nThe drug is currently being considered for approval in Canada after its shares lost value due to lack of evidence about its benefits. Now that Canadian authorities have given the green light, analysts expect full approval within a few months.", "llama3.2:3b": "GW Pharmaceuticals' prescription cannabis drug Sativex is set for approval in Canada for treating multiple sclerosis symptoms. Canadian authorities have accepted a qualifying notice, and analysts expect full approval early in 2005. The UK government granted GW Pharma a licence to grow cannabis for medical research, and the company's shares rose 8.1% after receiving the news.", "gemma2:2b": "GW Pharmaceuticals' prescription cannabis drug Sativex is set for approval in Canada, potentially making it the first cannabis-based drug approved globally. This follows recent delays and regulatory challenges regarding the drug's approval in the UK. Canada has expressed a strong interest in approving Sativex for MS sufferers, which could have significant implications for patients with the condition worldwide. \n", "qwen2.5:0.5b": "GW Pharmaceuticals plans to make a cannabis-based drug called Sativex available for use in Canada soon after it received regulatory approval from Health Canada. This is significant because this marks the first time a cannabis-based drug has been approved anywhere in the world. The company hopes that Sativex will be legal to consume within Canada, following on from its recent success with Satifex. Analysts are optimistic about the outcome as they see Sativex as a valuable treatment option for MS sufferers, who have struggled to find adequate medical care elsewhere due to drug shortages in many countries. Sativex's approval could also pave the way for other cannabis-based drugs being made available in the future.", "qwen2.5:1.5b": "GW Pharmaceuticals' cannabis-based drug, Sativex, will be approved for sale in Canada to treat MS patients within a few months, making it the first legal cannabis-based medication worldwide and potentially boosting GW's stock price. The UK government licensed its cultivation for research purposes, with thousands of plants grown secretly near London.", "qwen2.5:3b": "A prescription cannabis drug made by UK biotech firm GW Pharmaceuticals is set for approval in Canada to treat multiple sclerosis (MS). Initially facing regulatory scrutiny over benefits evidence, Canadian authorities have now approved the Sativex mouth spray. Approximately 50,000 Canadians and around 85,000 Britons suffer from MS; many already use cannabis medicinally. GW Pharma\u2019s drug could become the first globally approved cannabis-based treatment for MS within months. Analysts predict swift approval in Canada, following UK regulatory approval last year which faced delays. This represents a significant milestone for both GW Pharma and patients. Shares in the company rose significantly after this news, indicating investor optimism about future prospects.", "opencoder:1.5b": "The company is hopeful that the prescription cannabis drug from UK biotech firm GW Pharmaceuticals could be approved in Canada. As of now, approximately 50,000 people have been diagnosed with MS and 85,000 people are suffering from the condition in the UK. Many patients are already using cannabis to relieve their symptoms. The approval process has led to a new landmark for GW Pharma and for patients with MS. With its legal availability in Canada within the next few months, it will be considered for approval by regulatory bodies. The news of the first launch confirms the company's intention to start Sativex in Canada earlier this year, according to the UK government.\n", "smollm:1.7b": "The summary is concise and clear, preserving key ideas and details from the original text while omitting unnecessary information. It provides a brief overview of the cannabis industry, the approval process for GW Pharmaceuticals' Sativex drug, and the potential impact on Canadian patients with MS. The tone remains neutral and informative, avoiding explanations or justifications for the content.", "deepseek-r1:1.5b": "<think>\nOkay, I need to summarize the given text concisely while preserving key ideas and details. Let me read through the provided text carefully.\n\nThe main points are: a UK biotech firm, GW Pharmaceuticals, has approved their Sativex drug for Canada. It's used for treating the central nervous system and relieves symptoms of MS in the US and UK. Significant growth of medical research plants in England is expected. UK regulators had concerns but it passed now. The company's executive is happy about this development.\n\nI should focus on the main achievements: approval, potential legal access, market growth for research, and the effect on the stock price. I'll structure the summary to highlight these points clearly without unnecessary details.\n</think>\n\nGW Pharmaceuticals (GW Pharma) has successfully approved their Sativex drug for Canada, marking a significant step in its medical research journey. The drug addresses symptoms of multiple sclerosis, aiding both the US and UK. GW Pharma is expecting full regulatory approval within six months of launch, setting new standards for cannabis-based treatments. UK regulators initially had concerns but have since approved the product. This marks the first global approval from health authorities, a milestone for GW Pharma and its patients with MS. The drug will become legally available in Canada soon, and shares in GW Pharma have risen due to positive news.", "tinyllama:1.1b": "Cannabis firm GW Pharmaceuticals has received approval from Canadian regulators for a drug used to treat multiple sclerosis (MS). The cannabidiol and tetrahydocannabinoid mixture Sativex will be legalized in Canada within the next few months, making it the first time a cannabis-based medicine has been approved anywhere in the world. In the UK, GW Pharmaceuticals received approval for its Sativex mouth spryder last year but was later delayed by regulatory issues. The company's shares have risen after news that Canada will soon receive a licence to grow cannabis plants for medical research purposes.", "tinydolphin:1.1b": " Cannabis is set to be approved in Canada for use in treating multiple sclerosis. This approval is a significant milestone in the history of medical cannabis and is expected to have far-reaching effects on patients suffering from this debilitating condition. GW Pharmaceuticals, the UK biotech firm responsible for the development of Sativex, has made great progress towards approval in Canada, where it hopes to offer relief to those suffering from MS and other neurological ailments.\n\nSativex is an oral cannabis spray containing a blend of tetrahydrocannabinol and cannabidiol, two compounds known to have therapeutic effects on the central nervous system. The cannabinoids in Sativex are derived from the same plant species used to produce marijuana, but they possess unique properties that make them more effective for treating MS symptoms. These properties include reducing inflammation and promoting relaxation in patients with multiple sclerosis.\n\nThe approval of Sativex by Health Canada will be a significant step forward for GW Pharma's development efforts, paving the way for full approval in Canada. Once approved, Canadian authorities expect to grant final approval within the next few months, and the company anticipates receiving regulatory approval for Sativex in the early part of 2005.\n\nCanada is a significant market for medical cannabis products, with more than 50,000 patients already using cannabinoids to alleviate symptoms such as seizures and muscle spasms. The approval of Sativex in Canada will undoubtedly boost the company's reputation for bringing innovative treatments to patients suffering from debilitating conditions. As more countries around the world legalize medical cannabis, there will be an increasing demand for products like Sativex, and GW Pharma is well positioned to capitalize on this trend.", "phi:2.7b": " The text reports that GW Pharmaceuticals' cannabis-based drug, Sativex, is being considered for approval in Canada, potentially becoming the first approved cannabis-based drug worldwide. This could significantly impact the company and patients suffering from multiple sclerosis (MS). The drug's future approval in the UK has been delayed, causing a temporary drop in shares.\n", "orca-mini:3b": " Canadian authorities have announced that a prescription cannabis drug made by UK biotech firm GW Pharmaceuticals will be approved for use in Canada. The drug is used to treat the central nervous system and alleviate the symptoms of multiple sclerosis (MS).", "hermes3:3b": "GW Pharmaceuticals cannabis drug for MS approved in Canada", "stablelm-zephyr:3b": "GW Pharmaceuticals' prescription cannabis drug, Sativex, is set to receive approval in Canada for treating central nervous system issues and alleviating multiple sclerosis (MS) symptoms. Canadian authorities have confirmed consideration for approval, marking a milestone for the UK biotech firm and patients with MS. The drug consists of a cannabis extract containing tetrahydrocannabinol and cannabidiol, also effective in treating arthritis. GW Pharma received a licence to grow the cannabis plant for medical research purposes from the UK government. The company anticipates full approval for Sativex in Canada early 2005.", "chatgpt-4o-latest": "GW Pharmaceuticals' cannabis-based drug, Sativex, is set to be approved in Canada for treating multiple sclerosis (MS) symptoms. This follows a setback in the UK, where regulators requested more evidence of its benefits. If approved, Sativex will be the first cannabis-based drug legally available worldwide. Canada has around 50,000 MS patients, many of whom already use cannabis for symptom relief. GW Pharma expects full approval in early 2005. The UK government has licensed the company to grow cannabis for medical research, and Sativex has also shown effectiveness in treating arthritis. The news boosted GW Pharma's shares by 8.1%.", "stablelm2:1.6b": "UK biotech firm GW Pharmaceuticals' prescription cannabis drug, Sativex, is set for approval in Canada for treating multiple sclerosis (MS) and central nervous system symptoms. Its approval was initially delayed due to UK regulators seeking more evidence on its benefits but now Canadian authorities are considering it. Approximately 100,0..\nGW Pharma's Sativex mouth spray could be legally available to MS sufferers in Canada within the next few months, marking a landmark for GW Pharma and patients with MS. Final approval is expected soon, and the company expects full approval for Sativex early this year.", "granite3.1-dense:2b": "Canada is set to approve GW Pharmaceuticals' prescription cannabis drug Sativex for treating multiple sclerosis (MS) symptoms, marking the first global authorization of a cannabis-based medication. This decision follows initial UK regulatory concerns about the drug's benefits but is expected to be formalized soon. Approximately 50,000 Canadians and 85,000 UK residents live with MS, many of whom already use cannabis to alleviate symptoms. Sativex, a cannabis mouth spray, contains tetrahydrocannabinol and cannabidiol, proven effective for arthritis treatment as well. GW Pharma grows the required cannabis plants in secret locations within England's countryside. Despite previous delays, this positive development has boosted GW Pharma shares by 8.1%.", "reference": "A prescription cannabis drug made by UK biotech firm GW Pharmaceuticals is set to be approved in Canada.\"We are delighted to receive this qualifying notice from Health Canada and look forward to receiving regulatory approval for Sativex in Canada in the early part of 2005,\" said GW Pharma executive chairman Dr Geoffrey Guy.This will be the first time a cannabis-based drug has been approved anywhere in the world, representing a landmark for GW Pharma and for patients with MS.The UK government granted GW Pharma a licence to grow the cannabis plant for medical research purposes.A few weeks ago, shares in GW Pharma lost a third of their value after UK regulators said they wanted more evidence about the drug's benefits.But now Canadian authorities have said the Sativex drug will be considered for approval."}